Skip to main content
SpringerLink
Log in

Bone Health: Prevention of Skeletal-Related Events and Palliative Care

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2936 Accesses

Abstract

Bone health in patients with prostate cancer has been an ever-growing field for almost a decade now. Beyond the realization that patients with prostate cancer suffer from osteopenia at the outset and need some sort of regimen to maintain their bone density, it is becoming increasingly clear that bone decay related to hormonal therapies can result in fractures, which may correlate negatively with overall survival. Preventing bone attrition may not only help avoid these fractures but may also render the bone microenvironment inhospitable to circulating cancer cells. Even patients with metastatic disease who will experience bone complications related to their metastases can now benefit from prophylactic therapies to avoid these complications. Besides serving this purpose, some of these therapies may in fact have antitumoral effects. This chapter deals with bone health at various phases of the natural history of prostate cancer, with a special emphasis on novel bone-targeted treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ADT:

Androgen-deprivation therapy

BALP:

Bone-specific alkaline phosphatase

BMD:

Bone mineral density

BP:

Bisphosphonate

CRPC:

Castration-resistant prostate cancer

CTC:

Circulating tumor cell

CTIBL:

Cancer treatment-induced bone loss

CTX:

C-telopeptide of type I collagen

DTC:

Disseminated tumor cell

GU:

Genitourinary

HR:

Hazard ratio

N-BP:

Nitrogen-containing bisphosphonate

NTX:

N-telopeptide of type I collagen

OS:

Overall survival

PC:

Prostate cancer

PO:

Oral(ly)

PSA:

Prostate-specific antigen

RANK:

Receptor activator of nuclear factor kappa B

RANKL:

Receptor activator of nuclear factor kappa B ligand

RP:

Radical prostatectomy

SC:

Subcutaneous(ly)

SRE:

Skeletal-related event

ZA:

Zoledronic acid

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60(5):227–300.

    Article  Google Scholar 

  2. Yossepowitch O, Bianco Jr FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007;51(4):940–7.

    Article  PubMed  Google Scholar 

  3. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008;179(1):156–61.

    Article  PubMed  Google Scholar 

  4. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2010;117(10):2077–85.

    Article  PubMed  Google Scholar 

  5. Bruce I, Carlin GLA. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88:2989–94.

    Article  Google Scholar 

  6. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer. 2009;115(19):4470–6.

    Article  PubMed  Google Scholar 

  7. Antonarakis ES, Blackford AL, Garrett-Meyer E, Eisengerger MA. J Clin Oncol. 2007;25(31):4998–5008.

    Article  PubMed  CAS  Google Scholar 

  8. Grob JC, Lallot C, Methlin G, Bollack C. Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer. Eur Urol. 1988;15(3–4):193–5.

    PubMed  CAS  Google Scholar 

  9. Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Ihde DC. Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma. Radiology. 1983;146(2):513–8.

    PubMed  CAS  Google Scholar 

  10. Zaragoza MR, Grossman HB. Objective treatment response to endocrine therapy in metastatic prostate cancer. Urology. 1992;40(5):405–8.

    Article  PubMed  CAS  Google Scholar 

  11. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007;110(1):81–6.

    Article  PubMed  Google Scholar 

  12. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.

    Article  PubMed  CAS  Google Scholar 

  13. Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer. 2003;2:34–40.

    Article  PubMed  Google Scholar 

  14. Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology. 2010;76(5):1175–81.

    Article  PubMed  Google Scholar 

  15. Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 2009;103(12):1641–6. Epub 2009 Feb 6.

    Article  PubMed  CAS  Google Scholar 

  16. Armstrong AJ, Garrett-Mayer ES, Yang YC, et al. Clin Cancer Res. 2007;13(21):6396–403.

    Article  PubMed  CAS  Google Scholar 

  17. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.

    Article  PubMed  CAS  Google Scholar 

  18. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.

    Article  PubMed  CAS  Google Scholar 

  19. Paget S. The distribution of secondary growth in cancer of the breast. Lancet. 1889;1:571–3.

    Article  Google Scholar 

  20. Boyle WJ, Simone WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.

    Article  PubMed  CAS  Google Scholar 

  21. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  PubMed  CAS  Google Scholar 

  22. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003;9:2587–97.

    PubMed  CAS  Google Scholar 

  23. Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4:380–4.

    Article  PubMed  Google Scholar 

  24. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane review). In. The Cochrane library, ed., issue 2. Chichester: Wiley; 2004.

    Google Scholar 

  25. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277–84.

    Article  PubMed  CAS  Google Scholar 

  26. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235–42.

    PubMed  CAS  Google Scholar 

  27. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

    Article  PubMed  CAS  Google Scholar 

  28. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038–42.

    Article  PubMed  CAS  Google Scholar 

  29. Josson S, Matsuoka Y, Chung LW, et al. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol. 2010;21:26–32.

    Article  PubMed  CAS  Google Scholar 

  30. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.

    Article  PubMed  CAS  Google Scholar 

  31. Rucci N, Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed). 2010;2:907–15.

    Article  Google Scholar 

  32. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.

    PubMed  CAS  Google Scholar 

  33. Clyburn RD, Reid P, Evans CA, et al. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol. 2010;65:969–78.

    Article  PubMed  CAS  Google Scholar 

  34. Coxon JP, Oades GM, Kirby RS, et al. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004;94:164–70.

    Article  PubMed  CAS  Google Scholar 

  35. Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and Taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:543–8.

    Article  PubMed  CAS  Google Scholar 

  36. Morgan C, Lewis PD, Jones RM, et al. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol. 2007;46:669–77.

    Article  PubMed  CAS  Google Scholar 

  37. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005;113:364–71.

    Article  PubMed  CAS  Google Scholar 

  38. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011. doi:10.1016/S0140-6736(10)62344-6.

  39. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9 suppl 1:S7.

    Article  PubMed  Google Scholar 

  40. Smith MR, Egerdie B, Hernàndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.

    Article  PubMed  CAS  Google Scholar 

  41. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–91.

    Article  PubMed  Google Scholar 

  42. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9 Suppl 4:28–37.

    Article  PubMed  CAS  Google Scholar 

  43. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420–32.

    Article  PubMed  CAS  Google Scholar 

  44. Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis. 2008;11:13–9.

    Article  PubMed  CAS  Google Scholar 

  45. Coleman RE, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008;34:629–39.

    Article  PubMed  CAS  Google Scholar 

  46. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology. 2003;61:993–8.

    Article  PubMed  Google Scholar 

  47. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.

    Article  PubMed  CAS  Google Scholar 

  48. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.

    Article  PubMed  CAS  Google Scholar 

  49. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12:3361–7.

    Article  PubMed  CAS  Google Scholar 

  50. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007;70:315–9.

    Article  PubMed  Google Scholar 

  51. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201.

    Article  PubMed  CAS  Google Scholar 

  52. Izumi K, Mizokami A, Narimoto K, et al. The role of bone turnover markers in patients with bone metastatic prostate cancer receiving zoledronate infusion [poster]. Presented at: American Society of Clinical Oncology 2010 genitourinary cancers symposium, San Francisco, 5–7 Mar 2010. Abstract 196.

    Google Scholar 

  53. Costa L, Cook R, Body J-J, et al. Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption [poster]. Presented at: The IX international meeting on cancer induced bone disease, Arlington, 28–31 Oct 2009. Poster 50.

    Google Scholar 

  54. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-­metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trail. Lancet. 2012;379(9810):39–46.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank the Société des Urologues Associés du CHUM for their support.

Conflict of Interest

Dr. Saad has served as an advisor and conducted research for Novartis and Amgen and has received funding for medical editorial assistance from Novartis.

Dr. Lattouf has served as an advisor and conducted research for Novartis and Amgen.

Author information

Authors and Affiliations

  1. Department of Surgery, Notre-Dame Hospital, University of Montreal Hospital Center (CHUM), 1560 Sherbrooke East Street, Pavillon Mailloux, Room K5224, Montreal, QC, H2L 4M1, Canada

    Jean-Baptiste Lattouf M.D., FRCS (C) & Fred Saad M.D., FRCS (C)

Authors
  1. Jean-Baptiste Lattouf M.D., FRCS (C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fred Saad M.D., FRCS (C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fred Saad M.D., FRCS (C) .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Lattouf, JB., Saad, F. (2013). Bone Health: Prevention of Skeletal-Related Events and Palliative Care. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_78

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_78

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation